HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.

Abstract
The combination of mitoxantrone with lucanthone, a schistosomicidal and nonmyelotoxic agent, yielded a therapeutic synergism in L 1210 and P 388 leukemia with no increase in toxicity. In that combination the nonmyelotoxic lucanthone enabled the use of the optimal dose of mitoxantrone. The recent hypothesis that planar polycyclic aromatic compounds, mostly comprised by the term intercalators, intercalate with DNA or bind to DNA may need receiving with respect to membrane target sites.
AuthorsH Osswald, M Youssef
JournalJournal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 111 Issue 2 Pg. 137-40 ( 1986) ISSN: 0171-5216 [Print] Germany
PMID2939092 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anthraquinones
  • Intercalating Agents
  • Mitoxantrone
  • Lucanthone
Topics
  • Animals
  • Anthraquinones (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Drug Synergism
  • Female
  • Intercalating Agents (therapeutic use)
  • Leukemia L1210 (drug therapy)
  • Leukemia P388 (drug therapy)
  • Leukemia, Experimental (drug therapy)
  • Lucanthone (therapeutic use)
  • Mice
  • Mice, Inbred DBA
  • Mitoxantrone
  • Neoplasm Transplantation
  • Specific Pathogen-Free Organisms
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: